7/23/2019 Diagnosis Copd

1/12

SINTYA

1210211132

Global Strategy for Diagnosis, Management andPrevention of COPD

Combined Assessment of

COPD

7/23/2019 Diagnosis Copd

2/12

Global Strategy for Diagnosis, Management and Prevention of COPD

Combined Assessment of COPD

Risk

(GOLD

ClassificationofAirflow

Limitation)

Risk

(Exacerbation

history)

> 2

1

0

(C) (D)

(A) (B)

mMRC 01

C!" # 10

$

%

2

1

mMRC > 2

C!" > 10

Symptoms(mMRC or C!" score))

7/23/2019 Diagnosis Copd

3/12

COPD Assessment Test (CAT): An 8-item measure of health statusimpairment in COPD

http!""#atestonline$org%$

Breathlessness Measurement using the

Modifed British Medical ResearchCouncil (mMRC) Questionnaire!relates&ell to other measures of health status

and predi#ts future mortality ris'$

Global Strategy for Diagnosis, Management and Prevention ofCOPD

Assessment of Symptoms

7/23/2019 Diagnosis Copd

4/12

COPD Assessment (est CA(%

Measures health status

)ased on 8 *uestions

S#ore from + to

igh s#ores . symptoms May predi#t e/a#erbation

htt&'*catestonline*or+en+lishin,ex*htm

7/23/2019 Diagnosis Copd

5/12

Global Strategy for Diagnosis, Management and Prevention ofCOPD

Mo,ifie, MRC (mMRC)-.estionnaire

7/23/2019 Diagnosis Copd

6/12

Global Strategy for Diagnosis, Management and Prevention of COPD

Combined Assessment of COPD

(C) (D)

(A) (B)

mMRC 01

C!" # 10

mMRC > 2

C!" > 10

Symptoms(mMRC or C!" score))

/f mMRC 01 or C!" # 10' Less ym&toms (! or C)

/f mMRC > 2 or C!" > 10'

More ym&toms ( or D)

!ssess sym&toms first

7/23/2019 Diagnosis Copd

7/12

Global Strategy for Diagnosis, Management and Preventionof COPD

Classi0#ation of Severity of

Air1o& 2imitation in COPD34n patients &ith 567"57C 9 +$:+!

GO2D ! Mild 567; 8+< predi#ted

GO2D =! Moderate +< 9 5679 8+! Severe >+< 9 5679 + 2

1

0

(C) (D)

(A) (B)

mMRC 01

C!" # 10

$

%

2

1

mMRC > 2

C!" > 10

Symptoms(mMRC or C!" score))

4f GO2D or = and only+ or e/a#erbations per

year!2o& @is' A or )%

4f GO2D > or ? ort&o or

more e/a#erbations peryear!

igh @is' C or D%

!ssess ris of exacerbations next

7/23/2019 Diagnosis Copd

9/12

Global Strategy for Diagnosis, Management and Prevention of COPD

Combined Assessment of COPD

Risk

(GOLD

ClassificationofAirflow

Limitation)

Risk

(E

xacerbationhistor

y)

> 2

1

0

(C) (D)

(A) (B)

mMRC 01

C!" # 10

$

%

2

1

mMRC > 2

C!" > 10

Symptoms(mMRC or C!" score))

Patient is no& in one offour #ategories!

A! 2ess symptoms, lo&ris'

)! More symptoms, lo&

ris'

C! 2ess symptoms, highris'

D! More symptoms, highris'

3se combine, assessment

7/23/2019 Diagnosis Copd

10/12

Patient Characteristic SpirometricClassification

Exacerbationsper year

mRC CA!

!Lo Ris

Less ym&tomsGOLD 12 4 1 01 # 10

Lo Ris

More ym&toms GOLD 12 4 1 > 2 5 10

C6i+h Ris

Less ym&tomsGOLD %$ > 2 01 # 10

D6i+h Ris

More ym&tomsGOLD %$ > 2 > 2

5 10

Global Strategy for Diagnosis, Management and Preventionof COPD

Combined Assessment of

COPD

When assessing risk, choose the highestrisk

according to GOLD grade or exacerbation history

7/23/2019 Diagnosis Copd

11/12

Global Strategy for Diagnosis, Management and Prevention of COPD

Manage Stable COPD! Pharma#ologi# (herapy(Medications in each %o& are mentioned in al'ha%etical order and thereore notnecessaril in order o 'reerence+)

Patient "irst choice Secon# choice Alternati$e Choices

!!M! &rn

or!! &rn

7L!M!or

L!!or

!! an, !M!

"heo&hylline

7L!M!

orL!!

7L!M! an, L!!!! and/or!M!

"heo&hylline

C

7/C 8 L!!

or7L!M! 7L!M! an, L!!

79DE$inh*

!! an,or!M!"heo&hylline

D

7/C 8 L!!or

7L!M!

/C an, 7L!M! or7/C 8 L!! an, 7L!M! or

7/C8L!! an, 79DE$inh* or7L!M! an, L!! or

7L!M! an, 79DE$inh.

Carbocysteine!! an,or!M!

"heo&hylline

7/23/2019 Diagnosis Copd

12/12